StrokeNCT07475611
Effectiveness of an Interactive Screen in the Rehabilitation of Neglect in Adults With Subacute Stroke: A Randomized Controlled Trial in Argentina.
A study testing Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect and occupational therapy conventional treatment in people with Stroke and Neglect, Hemispatial, run by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia at 1 site in Argentina.
Trial summary
Hemispatial neglect is one of the most frequent and disabling sequelae after a stroke, particularly following right-hemisphere lesions. Its prevalence ranges from 25% to 80% and is associated with poorer functional outcomes, increased risk of falls, prolonged hospital stays, and lower rates of discharge to home. Read more about this study
- Who is it for?
- Ages 18 to 88 years
- Conditions the study is for
- Stroke, Neglect, Hemispatial
- What is being tested?
- Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect and occupational therapy conventional treatment
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteArgentina
- Study dates
- 1 Oct 2025to 1 May 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 88 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Right-sided stroke. Ischemic or hemorrhagic.
- Currently in the subacute phase of recovery from the event (1 week to <6 months post-stroke).
- Presence of left hemineglect as determined by the Catherine Bergego Scale and/or Cancel Bells Test and/or Line Bisection Test.
- Age 18 to 88 years.
- Native Spanish speaker.
Who cannot join
- Bilateral stroke. Previous strokes.
- Medically unstable condition.
- Previous visual impairments that prevent interaction with the device screen.
- Presence of severe left homonymous hemianopsia. Determined by the total absence of vision in the entire left visual field, evaluated by confrontation visual field testing during the neurological physical examination.
- Severe aphasia that prevents the comprehension of simple instructions that guarantee the completion of the task, determined by an NIHSS scale with a score of 3 points on the aphasia subitem.
- Severe attentional and executive function deficits that prevent the comprehension of simple instructions, determined by the Catherine Bergego Scale and/or Cancel Bells Test and/or Line Bisection Test.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Hemispatial neglect is one of the most frequent and disabling sequelae after a stroke, particularly following right-hemisphere lesions. Its prevalence ranges from 25% to 80% and is associated with poorer functional outcomes, increased risk of falls, prolonged hospital stays, and lower rates of discharge to home. In response to these challenges, rehabilitation technologies have emerged as promising tools, especially during the subacute phase of stroke, a critical period for neuroplasticity. The MYRO® device-an adjustable interactive screen that enables intensive, task-oriented training-has shown benefits in promoting visual scanning, midline crossing, and sensorimotor integration through personalized exercises with constant feedback.
This study aims to evaluate the effectiveness of MYRO® combined with conventional occupational therapy in patients with left hemispatial neglect secondary to subacute stroke. A randomized clinical trial will be conducted with 30 participants assigned to two groups: conventional occupational therapy (OT-C) and occupational therapy plus rehabilitation technology using MYRO® (OT-M). Both groups will receive interventions for four weeks, with assessments at baseline, at the end of the protocol, and at a six-week follow-up. Outcome measures will include the NIHSS, FIM, Catherine Bergego Scale, Cancelation Bells Test, and Line Bisection Test.
It is expected that the use of MYRO® will enhance visuospatial attention toward the left hemifield and accelerate functional recovery compared with conventional treatment alone. The results could provide relevant evidence supporting the integration of interactive technology into neurofunctional rehabilitation within the Argentine context.
- Conditions
- Stroke, Neglect, Hemispatial
- Being tested
- Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect, occupational therapy conventional treatment
- Keywords
- neglect, stroke, rehabilitation, virtual reality
- Medical subject headings
- Stroke, Perceptual Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglectDevice
Use of the Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect
occupational therapy conventional treatmentOther
Bottom - up, restorative occupational therapy approach to unilateral neglect
| Study group | Role | What they receive |
|---|---|---|
| Neglect Conventional intervenction | Other | Conventional occupational therapy intervention for the treatment of neglect Receives: Other: occupational therapy conventional treatment |
| Neglect Virtual Intervention | Experimental | Use of an interactive screen for neglect rehabilitation Receives: Device: Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect |
What is being measured
The primary outcome is the main question the study is designed to answer.
Catherine Bergego Scale for Neglect
The Catherine Bergego Scale (CBS) is a functional assessment composed of 10 items, each scored on a 0-3 scale, resulting in a total score ranging from 0 to 30. A score of 0 indicates the absence of neglect, whereas a score of 30 reflects severe unilateral neglect. Higher total scores represent worse performance and greater severity of neglect, while lower scores indicate better functional outcomes. Severity levels are commonly categorized as follows: 1-10 points indicate mild behavioral neglect, 10-20 indicate moderate neglect, and 21-30 represent severe behavioral neglect.
Measured: from the start of treatment until 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2026
- Study start1 Oct 2025
- Primary completion1 Dec 2026 (estimated)
- Study completion1 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- ensayo clínico aleatorizado y con dos ramas
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Vanina Lado, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
- Investigators
- Vanina Lado, Study director, Fundacion para la Lucha de las Enfermedades Neurologicas de la Infancia, Sede Escobar
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07475611
- Sponsor's protocol ID
- 14/25
- Status last verified
- Mar 2026
- First submitted
- 5 Mar 2026
- Last updated
- 16 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Only IPDs used for the publication of the results will be included.
Publications
Williams LJ, Kernot J, Hillier SL, Loetscher T. Spatial Neglect Subtypes, Definitions and Assessment Tools: A Scoping Review. Front Neurol. 2021 Nov 24;12:742365. doi: 10.3389/fneur.2021.742365. eCollection 2021.
PubMed 34899565Williams LJ, Loetscher T, Hillier S, Hreha K, Jones J, Bowen A, Kernot J. Identifying spatial neglect - an updated systematic review of the psychometric properties of assessment tools in adults post-stroke. Neuropsychol Rehabil. 2025 Apr;35(3):628-667. doi: 10.1080/09602011.2024.2346212. Epub 2024 May 10.
PubMed 38727637